From: Ventricular assist devices as bridge to heart transplantation: impact on post-transplant infections
 | No VAD (n = 84) | VAD (n = 35) |
---|---|---|
Follow-up, years; mean (SD) | 1.38 (1.07) | 1.31 (1.06) |
Recipient age, years; mean (SD) | 47.9 (16.9) | 45.7 (16.7) |
Recipient gender, male; n (%) | 62 (73.8) | 28 (80) |
Donor age, years; mean (SD) | 41.3 (16.5) | 40.7 (15.0) |
Donor gender, male; n (%) | 48 (57.1) | 24 (68.6) |
Prior diabetes; n (%) | 15 (17.9) | 4 (11.4) |
BMI, kg/m2; mean (SD) | 24.4 (4.7) | 25.2 (4.8) |
Serum creatinine, umol/l; mean (SD) | 125.9 (66.0) | 103.3 (47.1) |
Underlying disease; n (%) | Â | Â |
 - Cardiomyopathy  - Ischemic  - Congenital heart disease  - Other | 41 (48.8) 23 (27.4) 5 (5.9) 15 (17.9) | 18 (51.4) 12 (34.3) 1 (2.9) 4 (11.4) |
Cold ischemia, min; mean (SD) | 151 (54.3) | 164 (54.4) |
Bypass time, min; mean (SD) | 168 (65.6) | 186 (71.1) |
Induction therapy; n (%) | Â | Â |
 - Basiliximab  - ATG  - None | 7 (8.3) 71 (84.5) 6 (7.1) | 6 (17.1) 24 (68.6) 5 (14.3) |
Maintenance at discharge; n (%) | Â | Â |
 - Tacrolimus  - Cyclosporin  - MMF/MPA  - Azathioprine  - Everolimus  - Steroids | 28 (33.3) 39 (46.4) 63 (75.0) 21 (25.0) 9 (10.7) 74 (88.1) | 10 (28.6) 13 (37.1) 22 (62.9) 7 (20.0) 3 (8.6) 27 (77.1) |